Business & Finance
Sun Pharma reports FY22 full year results
31 May 2022 -

Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA, BSE: 524715) reported on Monday financials for the fourth quarter & full year ending 31 March 2022.

For the full year FY22 consolidated sales from operations was INR384,26m, a growth of 15.6% over last year. R&D investments was at INR22,194m compared to INR21,499m for FY21. EBITDA was at INR101,697m, up about 23.6% over last year, with EBITDA margin at 26.5%, an expansion of 170bps YoY.

Excluding the exceptional items, adjusted net profit for FY22 was at INR76,671m, up about 29% YoY. Reported net profit for full year FY22 was at INR32,727m compared to INR29,038m, up by about 13% over last year

These results were taken on record by the company's board of directors at a meeting held on Monday 30 May 2022. The board has proposed a final dividend of INR3.0 per share for the year FY22. This is in addition to the interim dividend of INR7.0 per share paid in FY22, taking the total dividend for FY22 to INR10.0 per share compared to INR7.5 per share for FY21.

Dilip Shanghvi, Sun Pharmaceutical Industries managing director, said, 'FY22 was a good year with strong topline and EBITDA growth. All our geographies have recorded double digit growth and profitability has improved despite rising costs. The specialty business continues to ramp-up strongly with global Ilumya sales recording 81% growth to reach USD315m in FY22. Our India business continues to grow faster than market, leading to increase in market share. We continue to focus on expanding our global specialty business, growing all our businesses and on improving operational efficiencies.'